Reticulohistiocytoma Overview

Save information for later
Sign Up

Learn About Reticulohistiocytoma

What is the definition of Reticulohistiocytoma?
Reticulohistiocytoma (RH) is a rare benign lesion of the soft tissue. It belongs to a group of disorders called non-Langerhans cell histiocytosis and is a type of reticulohistiocytosis, all of which are types of histiocytosis. Histiocytosis is a condition in which there is rapid production (proliferation) of histiocytes (immune cells) in the skin or soft tissues. The stimulus that causes the immune system to react in RH is currently not well understood. RH present as a yellow to reddish-brown smooth surfaced, firm nodule or lesion on the trunk and/or extremities of the body. Historically, RH has been found in young adults, with a slightly higher incidence in males.
What are the alternative names for Reticulohistiocytoma?
  • Reticulohistiocytoma
  • Solitary histiocytoma
  • Solitary reticulohistiocytosis
Who are the top Reticulohistiocytoma Local Doctors?
Jithma P. Abeykoon
Elite in Reticulohistiocytoma
Dr. Jithma P. Abeykoon
Hematology | Oncology | Hematology Oncology
Elite in Reticulohistiocytoma
Dr. Jithma P. Abeykoon
Hematology | Oncology | Hematology Oncology

Mayo Clinic

200 1st St Sw, 
Rochester, MN 
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jithma Abeykoon is a Hematologist and an Oncologist in Rochester, Minnesota. Dr. Abeykoon is rated as an Elite provider by MediFind in the treatment of Reticulohistiocytoma. His top areas of expertise are Waldenstrom Macroglobulinemia, Reticulohistiocytoma, Histiocytosis, Tissue Biopsy, and Bone Marrow Transplant. Dr. Abeykoon is currently accepting new patients.

Elite in Reticulohistiocytoma
Dr. Jasmine Francis
Hematology | Oncology
Elite in Reticulohistiocytoma
Dr. Jasmine Francis
Hematology | Oncology

Mskcc Surgery Group

160 E 53rd St, 
New York, NY 
212-610-0496
Languages Spoken:
English
See accepted insurances

Jasmine Francis is a Hematologist and an Oncologist in New York, New York. Dr. Francis is rated as an Elite provider by MediFind in the treatment of Reticulohistiocytoma. Her top areas of expertise are Retinoblastoma, Melanoma of the Eye, Metastatic Uveal Melanoma, Vitrectomy, and Liver Embolization.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Reticulohistiocytoma
J J. Haroche
Elite in Reticulohistiocytoma
J J. Haroche
Paris, FR 

J Haroche practices in Paris, France. Haroche is rated as an Elite expert by MediFind in the treatment of Reticulohistiocytoma. Their top areas of expertise are Histiocytosis, Reticulohistiocytoma, Erdheim-Chester Disease, Non-Langerhans-Cell Histiocytosis, and Tissue Biopsy.

View All Doctors
What are the latest Reticulohistiocytoma Clinical Trials?
Multi-Center Phase II Randomized Controlled Trial of Naïve T Cell Depletion for Prevention of Chronic Graft-Versus-Host Disease in Children and Young Adults
Multi-Center Phase II Randomized Controlled Trial of Naïve T Cell Depletion for Prevention of Chronic Graft-Versus-Host Disease in Children and Young Adults
Who is this study for: Infant to young adult patients with Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Thiotepa, Fludarabine, Cyclophosphamide, Busulfan, Tacrolimus, Methotrexate
Study Phase: Phase 2

Summary: This phase II trial studies how well naive T-cell depletion works in preventing chronic graft-versus-host disease in children and young adults with blood cancers undergoing donor stem cell transplant. Sometimes the transplanted white blood cells from a donor attack the body's normal tissues (called graft versus host disease). Removing a particular type of T cell (naive T cells) from the donor cell...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Multipart, Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
A Multipart, Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3

Summary: Hemophagocytic lymphohistiocytosis is a rare, aggressive and life-threatening syndrome of excessive immune activation. Secondary hemophagocytic lymphohistiocytosis (sHLH) is the most common form of this disease and is typically associated with several other clinical conditions (eg, malignancy associated HLH (mHLH), infection, or autoimmune disease). ELA026 is a fully human immunoglobulin G1 (IgG1)...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center